Disease Overview：Breast Cancer（BC）
Breast cancer is a malignant neoplasm originating in the mammary gland epithelium, most commonly ductal or lobular carcinoma. It remains the most frequently diagnosed malignancy among women globally, with risk factors including age, genetic predisposition (e.g., BRCA1/BRCA2 mutations), hormonal exposure, and lifestyle factors. Early detection via mammography, ultrasound, and MRI—followed by histopathological confirmation through core needle biopsy—is critical for staging (TNM classification) and guiding multimodal management. Treatment strategies are highly individualized and may include surgical resection (lumpectomy or mastectomy), sentinel lymph node biopsy, adjuvant radiotherapy, systemic therapies (chemotherapy, endocrine therapy for hormone receptor–positive disease, HER2-targeted agents like trastuzumab), and increasingly, immunotherapy and CDK4/6 inhibitors for advanced cases. Prognosis varies significantly by molecular subtype, stage at diagnosis, and treatment response, with five-year survival exceeding 90% for localized disease.
China offers compelling advantages for international patients seeking breast cancer care. The country hosts nationally accredited cancer centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—with NCCN-aligned protocols, multidisciplinary tumor boards, and extensive experience managing complex cases, including neoadjuvant therapy responders and recurrent/metastatic disease. Advanced technologies—including digital breast tomosynthesis, intraoperative ultrasound-guided localization, robotic-assisted surgery, and next-generation sequencing for genomic profiling—are widely deployed. Clinical outcomes align closely with global benchmarks: published data show comparable pathologic complete response rates and recurrence-free survival across early- and locally advanced stages. Crucially, high-quality care is delivered at approximately 30–50% lower cost than in the US or Western Europe, without compromising evidence-based standards.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients. Our services include verified hospital referrals, pre-arrival clinical coordination, transparent itemized pricing (covering diagnostics, surgery, pathology, and follow-up), visa support, multilingual interpretation, accommodation logistics, and post-treatment care coordination—ensuring continuity, clarity, and confidence throughout the journey.
Breast Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Breast Cancer (Oncology Department)
Non-Surgical / Systemic Therapy Options
*Eligibility*: Confirmed invasive carcinoma or high-risk DCIS; biomarker testing required (ER/PR/HER2/Ki-67).
- •Endocrine Therapy (e.g., Tamoxifen, Letrozole, Anastrozole)
- *Cost (3-month supply)*: - Generic tamoxifen: $18–$24 - Brand-name letrozole (Femara®): $120–$150 - Gonadotropin-releasing hormone agonist (e.g., goserelin): $280–$350/dose (monthly)
- •Anti-HER2 Targeted Therapy
- *Trastuzumab (IV, 6 mg/kg weekly × 12 weeks → 6 mg/kg q3w × 9 months)*: $2,100–$2,600/course - *Pertuzumab + trastuzumab + docetaxel (neoadjuvant)*: $4,800–$5,900/cycle (3 cycles)
- •Chemotherapy (Adjuvant/Neoadjuvant)
- *Per cycle cost*: $420–$780, depending on drug selection and dose intensity
- •Biomarker & Monitoring Labs (per test)
- FISH for HER2: $180–$220 - Oncotype DX (21-gene assay): $1,450–$1,750 - ctDNA monitoring (e.g., Guardant360®): $820–$980/test
Surgical / Procedural Options
*Eligibility*: Clinically operable disease (T1–T4aN0–N2, no distant metastasis); cardiac/pulmonary clearance required.
- •Lumpectomy + Sentinel Lymph Node Biopsy (SLNB)
- *Procedure fee*: $2,400–$3,100 - *Intraoperative pathology (frozen section)*: $180–$240
- •Mastectomy (Simple or Skin-Sparing)
- *Procedure fee*: $3,600–$4,900 - *Immediate reconstruction (implant-based)*: $5,200–$7,400 (separate billing)
- •Axillary Lymph Node Dissection (ALND)
Special/Complex Condition Management
- •Metastatic Disease (Bone/Liver/Lung):
- Liver-directed radioembolization (Y-90): $8,200–$10,500/session
- Neoadjuvant pembrolizumab + chemo: $6,300–$7,800/cycle (4 cycles)- •BRCA1/2 Mutation Carriers:
Quick Selection Guide
- •Early-stage, ER+/HER2−, budget-conscious (<$2,000): Lumpectomy + endocrine therapy (generic tamoxifen) + standard adjuvant radiation
- •Young premenopausal, high-grade, BRCA+: Mastectomy + bilateral risk-reducing surgery + ovarian suppression + CDK4/6 inhibitor (palbociclib: $1,900/month)
- •Locally advanced, HER2+: Neoadjuvant pertuzumab/trastuzumab/docetaxel → surgery → adjuvant trastuzumab → extended neratinib ($2,300/month × 1 year)
- •Elderly (>75), significant comorbidities: Endocrine monotherapy ± palliative radiation ($1,100–$1,600 total) — avoid chemotherapy/surgery unless symptomatic progression
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Breast Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Breast Cancer treatment with China top medical destinations:
